Načítá se...
Ticagrelor therapy and atrioventricular block: Do we need to worry?
Ticagrelor is a potent, direct P2Y12 antagonist with rapid onset of action and intense platelet inhibition, indicated in patients with acute coronary syndromes (ACS). This drug is usually well tolerated, but some patients experience serious adverse effects: Major bleeding; gastrointestinal disturban...
Uloženo v:
| Vydáno v: | World J Clin Cases |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Baishideng Publishing Group Inc
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5434317/ https://ncbi.nlm.nih.gov/pubmed/28560235 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12998/wjcc.v5.i5.178 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|